Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD.
Payam DehghaniDavide CaoUsman BaberJohny NicolasSamantha SartoriCarlo A PivatoZhongjie ZhangGeorge DangasDominick J AngiolilloCarlo BriguoriDavid J CohenStuart J PocockDariusz DudekMichael GibsonRobert J GilKurt HuberUpendra KaulRan KornowskiMitchell W KrucoffVijay KunadianShamir MehtaDavid J MoliternoE Magnus OhmanJavier EscanedGennaro SardellaSamin K SharmaRichard A ShlofmitzGiora WeiszBernhard WitzenbichlerStuart PocockRoxana MehranPublished in: European heart journal. Cardiovascular pharmacotherapy (2022)
Irrespective of the presence of DM, CKD, and their combination, ticagrelor monotherapy reduced the risk of bleeding without a significant increase in ischaemic events compared with ticagrelor plus aspirin.
Keyphrases
- chronic kidney disease
- antiplatelet therapy
- percutaneous coronary intervention
- acute coronary syndrome
- st elevation myocardial infarction
- st segment elevation myocardial infarction
- end stage renal disease
- acute myocardial infarction
- coronary artery disease
- combination therapy
- atrial fibrillation
- glycemic control
- coronary artery bypass grafting
- open label
- low dose
- type diabetes
- cardiovascular events
- heart failure
- clinical trial
- cardiovascular disease
- skeletal muscle
- double blind